Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | RiME: nivolumab, rucaparib and ramucirumab in advanced gastroesophageal cancer

Anwaar Saeed, MD, University of Kansas Medical Center, Kansas City, MO, discusses the Phase I/II RiME trial (NCT03995017), investigating the use of the triplet combination of nivolumab, rucaparib and ramucirumab in patients with microsatellite-stable advanced gastric or esophageal adenocarcinoma. The hope is to use this treatment in the second-line or maintenance setting. Previous studies in other cancers have supported the idea of combining a PARP inhibitor with immunotherapy. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.